40 related articles for article (PubMed ID: 38342656)
1. Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers.
Chambers C; Chitwood B; Smith CJ; Miao Y
iRadiology; 2024 Apr; 2(2):128-155. PubMed ID: 38708130
[TBL] [Abstract][Full Text] [Related]
2. Chronoimmunology: from preclinical assessments to clinical applications.
Oster H; Ray DW
Semin Immunopathol; 2022 Mar; 44(2):149-151. PubMed ID: 35257251
[No Abstract] [Full Text] [Related]
3. GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics.
Obeid K; Kanellopoulos P; Abouzayed A; Mattsson A; Tolmachev V; Nock BA; Maina T; Orlova A
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675174
[TBL] [Abstract][Full Text] [Related]
4. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.
Dalm SU; Sieuwerts AM; Look MP; Melis M; van Deurzen CH; Foekens JA; de Jong M; Martens JW
J Nucl Med; 2015 Oct; 56(10):1487-93. PubMed ID: 26251419
[TBL] [Abstract][Full Text] [Related]
5. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
6. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors.
Morgat C; MacGrogan G; Brouste V; Vélasco V; Sévenet N; Bonnefoi H; Fernandez P; Debled M; Hindié E
J Nucl Med; 2017 Sep; 58(9):1401-1407. PubMed ID: 28280221
[TBL] [Abstract][Full Text] [Related]
7. Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review.
Baun C; Naghavi-Behzad M; Hildebrandt MG; Gerke O; Thisgaard H
Semin Nucl Med; 2024 Mar; 54(2):256-269. PubMed ID: 38342656
[TBL] [Abstract][Full Text] [Related]
8. Theranostic Prospects of Gastrin-Releasing Peptide Receptor-Radioantagonists in Oncology.
Maina T; Nock BA; Kulkarni H; Singh A; Baum RP
PET Clin; 2017 Jul; 12(3):297-309. PubMed ID: 28576168
[TBL] [Abstract][Full Text] [Related]
9. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
Kurth J; Potratz M; Heuschkel M; Krause BJ; Schwarzenböck SM
Nuklearmedizin; 2022 Jun; 61(3):247-261. PubMed ID: 35668669
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
